Company Watch

Suven secures three Indian product patents

Our News Bureau - Hyderabad

Suven Life Sciences has announced that the Indian Patent Office has granted three product patents 208688, 208714 and 209540 corresponding to three New Chemical Entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases and these patents are valid until 2022. The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven that are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neuro-degenerative disorders like Alzheimer's, attention deficient hyperactivity, Huntington's, Parkinson's and schizophrenia.

Suven has so far filed 25 product patents under PCT, out of which ten have entered the national phase. Suven has already filed its first investigational new drug (IND) application with DCGI to conduct the clinical phase-I study on their developmental candidate SUVN-502. "We continue to work on G-protein coupled receptor (GPCR) targets to discover and develop molecules focusing on CNS disorders with unmet medical need and high market potential," says Venkat Jasti, Chief Executive Officer, Suven.

Since Septeber 2006, Suven has also been working as a collaborative research partner with Elli Lilly to discover and develop NCEs for unmet medical needs in CNS therapeutic area. Suven is a service provider of drug discovery and development support services to global pharmaceutical, life sciences and biotech companies in addition to their continued business interest and growth in contract research and manufacturing services (CRAMS).